Search

Your search keyword '"Maestroni, A."' showing total 2,217 results
Start Over Author "Maestroni, A."
2,217 results on '"Maestroni, A."'

102. Rigid and flexible ureteroscopy (URS/RIRS) management of paediatric urolithiasis in a not endemic country

Author

Stefania Ferretti, Monica Cuschera, Davide Campobasso, Claudia Gatti, Riccardo Milandri, Tommaso Bocchialini, Elisa Simonetti, Pietro Granelli, Antonio Frattini, and Umberto Vittorio Maestroni

Subjects
Flexible ureterescopy, Paediatric stone disease, RIRS, Laser lithotripsy, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Introduction: In the last years due to miniaturization of endoscopic instruments and percutaneous surgery, endourology has become very popular in paediatric urinary stone managment. We reported our single-centre experience in retrograde endoscopic procedures in children. Results and complications of URS/RIRS are discussed. Materials and methods: We retrospectively reviewed our experience in patients ≤ 16 years old affected by urinary stones who underwent URS/RIRS procedures performed by two surgeons with expertise in endourology. A total of 30 renal Units (RUs) underwent endoscopic procedures (URS, RIRS or both). Surgical complications according to the ClavienDindo’s classification and stone-free rate were evaluated at 3 months follow-up. Success of URS was defined as stone-free status after single procedure while RIRS success rate was considered as presence of residual stone fragments smaller than 4 mm at first procedure. Results: The mean age of our patients was 8 years, range 2- 16 years. A total of 30 renal units (RUs) underwent 40 endourological procedures (23 URS and 17 RIRS; 10 children underwent both procedures at the same time). 17/30 (56.6%) RUs were pre-stented before surgery. The stone-free status was achieved in 23/30 renal units treated, with a 76.6% success rate. The remaining 7 patients had residual stones greater than 4 mm and underwent further treatments. After a second surgery the stone-free rate turned out to be 93.3% (28/30 renal units). Conclusions: Rigid and flexible ureteroscopy (URS/RIRS) is a reliable technique for treatment of < 2 cm urinary stones in paediatric age group. It shows low rate of major complications and promising results in terms of stone-free rate.

Published
2021
Full Text
View/download PDF

107. Placental proteome abnormalities in women with gestational diabetes and large-for-gestational-age newborns

Author

Irene Cetin, Emma Assi, Francesca D'Addio, Chiara Mandò, Anna Maestroni, Cristian Loretelli, Moufida Ben Nasr, Vera Usuelli, Ahmed Abdelsalam, Andy Joe Seelam, Ida Pastore, Cinzia Magagnotti, Reza Abdi, Basset El Essawy, Franco Folli, Domenico Corradi, Gianvincenzo Zuccotti, and Paolo Fiorina

Subjects
Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Introduction Gestational diabetes mellitus (GDM) is the most frequent metabolic complication during pregnancy and is associated with development of short-term and long-term complications for newborns, with large-for-gestational-age (LGA) being particularly common. Interestingly, the mechanism behind altered fetal growth in GDM is only partially understood.Research design and methods A proteomic approach was used to analyze placental samples obtained from healthy pregnant women (n=5), patients with GDM (n=12) and with GDM and LGA (n=5). Effects of altered proteins on fetal development were tested in vitro in human embryonic stem cells (hESCs).Results Here, we demonstrate that the placental proteome is altered in pregnant women affected by GDM with LGA, with at least 37 proteins differentially expressed to a higher degree (p

Published
2020
Full Text
View/download PDF

110. Collateral presence and extent do not predict myocardial viability and ischemia in chronic total occlusions: A stress-CMR study

Author

S, Pica, L, Di Odoardo, L, Testa, M, Bollati, G, Crimi, A, Camporeale, L, Tondi, G, Pontone, M, Guglielmo, D, Andreini, A, Squeri, L, Monti, F, Roccasalva, L, Grancini, G L, Gasparini, G G, Secco, B, Bellini, L, Azzalini, A, Maestroni, F, Bedogni, and M, Lombardi

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Well-developed collaterals are assumed as a marker of viability and ischemia in chronic total occlusions (CTO). We aim to correlate viability and ischemia with collateral presence and extent in CTO patients by cardiac magnetic resonance (CMR).Multicentre study of 150 CTO patients undergoing stress-CMR, including adenosine if normal systolic function, high-dose-dobutamine for patients with akinetic/2 hypokinetic segments and EF ≥35%, otherwise low-dose-dobutamine (LDD); all patients underwent late gadolinium enhancement (LGE) imaging. Viability was defined as mean LGE transmurality ≤50% for adenosine, as functional improvement for dobutamine-stress-test, ischemia as ≥1.5 segments with perfusion defects outside the scar zone.Rentrop 3/CC 2 defined well-developed (WD, n = 74) vs poorly-developed collaterals (PD, n = 76). Viability was equally prevalent in WD vs PD: normo-functional myocardium with ≤50% LGE in 52% vs 58% segments, p = 0.76, functional improvement by LDD in 48% vs 52%, p = 0.12. Segments with none, 1-25%,26-50%,51-75% LGE showed viability by LDD in 90%,84%,81%,61% of cases, whilst in 12% if 76-100% LGE (p 0.01). There was no difference in WD vs PD for ischemia presence (74% vs 75%, p = 0.99) and extent (2.7 vs 2.8 segments, p = 0.77).In a large cohort of CTO patients, presence and extent of collaterals did not predict viability and ischemia by stress-CMR. Scar extent up to 75% LGE was still associated with viability, whereas ischemia was undetectable in 25% of patients, suggesting that the assessment of CTO patients with CMR would lead to a more comprehensive evaluation of viability and ischemia to guide revascularization.

Published
2023

111. MR-based simplified extraprostatic extension evaluation: comparison of performances of different predictive models

Author

Silvia Schirò, Gianluca Milanese, Michele Maddalo, Francesco Ziglioli, Umberto Vittorio Maestroni, Carmenlinda Manna, Roberta Eufrasia Ledda, Giulio Negrini, Francesco Mastrapasqua, Rocco Cobelli, Giacomo Tamburino, Maria Elena Conti, Silvia Luceri, Ludovica Leo, Caterina Ghetti, and Nicola Sverzellati

Subjects
Radiology, Nuclear Medicine and imaging, General Medicine
Abstract

To test reproducibility and predictive value of a simplified score for assessment of extraprostatic tumor extension (sEPE grade).Sixty-five patients (mean age ± SD, 67 years ± 6.3) treated with radical prostatectomy for prostate cancer who underwent 1.5-Tesla multiparametric magnetic resonance imaging (mpMRI) 6 months before surgery were enrolled. sEPE grade was derived from mpMRI metrics: curvilinear contact length15 mm (CCL) and capsular bulging/irregularity. The diameter of the index lesion (dIL) was also measured. Evaluations were independently performed by seven radiologists, and inter-reader agreement was tested by weighted Cohen K coefficient. A nested (two levels) Monte Carlo cross-validation was used. The best cut-off value for dIL was selected by means of the Youden J index to classify values into a binary variable termed dIL*. Logistic regression models based on sEPE grade, dIL, and clinical scores were developed to predict pathologic EPE. Results on validation set were assessed by the main metrics of the receiver operating characteristics curve (ROC) and by decision curve analysis (DCA). Based on our findings, we defined and tested an alternative sEPE grade formulation.Pathologic EPE was found in 31/65 (48%) patients. Average κsEPE grade is reproducible and when combined with the dIL* accurately predicts extraprostatic tumor extension.• Simple and reproducible mpMRI semi-quantitative scoring system for extraprostatic tumor extension. • sEPE grade accurately predicts extraprostatic tumor extension regardless of reader expertise. • Accurate pre-operative staging and risk stratification for optimized patient management.

Published
2022

112. Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

Author

Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, and Sebastiano Buti

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in therapy is not clearly established. It has comparable efficacy and better tolerability than sunitinib in clear cell renal carcinoma. Our objective was to review the use of pazopanib in metastatic nccRCC. Methods: We conducted a systematic review according to PRISMA guidelines. Any type of study reporting the use of pazopanib in metastatic renal cell carcinoma including cases with non-clear cell histology was eligible. Results: In all, 15 studies were included in our analysis, including a total of 318 nccRCC patients treated with pazopanib. Most studies were retrospective ( n = 12); three were prospective trials. The specific outcomes of nccRCC patients were reported by four studies. Pazopanib alone as first-line treatment gave overall response rates ranging from 27% to 33%, disease control rates of 81–89%, median progression free survival of 8.1–16.5 months and median overall survival of 17.3–31.0 months. Grade 3–4 adverse events rates were 21–55%. Conclusion: The present review provides for the first time a systematic summary of evidence about the possible use of pazopanib as first-line treatment for nccRCC, with a favorable outcome despite the low strength of evidence. Pazopanib could be considered as a possible therapeutic option in this setting.

Published
2020
Full Text
View/download PDF

113. The Effects of Formulation on Imidacloprid Dissipation in Grapes and Vine Leaves and on Required Pre-Harvest Intervals under Lebanese Climatic Conditions

Author

Liliane Majed, Salem Hayar, Rawan Zeitoun, Britt Marianna Maestroni, and Sylvie Dousset

Subjects
imidacloprid, vine leaves, grape, QuEChERS, SL and WDG formulation, dissipation, Organic chemistry, QD241-441
Abstract

In this study, imidacloprid, a systemic insecticide, currently having a specified European Commission MRL value for vine leaves (2 mg kg−1), was applied on a Lebanese vineyard under different commercial formulations: as a soluble liquid (SL) and water dispersible granules (WDG). In Lebanon, many commercial formulations of imidacloprid are subject to the same critical good agricultural practice (cGAP). It was, therefore, important to verify the variability in dissipation patterns according to matrix nature and formulation type. Random samplings of grapes and vine leaves were performed starting at 2 days until 18 days after treatment. Residue extractions were performed according to the QuEChERS method and the analytical determination using liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS). The SL formulation yielded significantly higher initial deposit than the WDG formulation on grapes and vine leaves. The formulation type did not significantly affect the dissipation rates; the estimated half-lives in grapes and vine leaves were 0.5 days for all imidacloprid formulations. No pre-harvest intervals were necessary on grapes. PHIs of 3.7 days for the SL formulation and 2.8 days for the WDG formulation were estimated on vine leaves. The results showed that the type of formulation and the morphological and physiological characteristics of the matrix had an effect on the initial deposits, and thus residue levels, but not on the dissipation patterns.

Published
2021
Full Text
View/download PDF

114. Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity

Author

Bersanelli, Melissa, primary, Gnetti, Letizia, additional, Pilato, Francesco Paolo, additional, Varotti, Elena, additional, Quaini, Federico, additional, Campanini, Nicoletta, additional, Rapacchi, Elena, additional, Camisa, Roberta, additional, Carbognani, Paolo, additional, Silini, Enrico Maria, additional, Rusca, Michele, additional, Leonardi, Francesco, additional, Maestroni, Umberto, additional, Rizzo, Mimma, additional, Brunelli, Matteo, additional, Buti, Sebastiano, additional, and Ampollini, Luca, additional

Published
2023
Full Text
View/download PDF

118. Do people with musculoskeletal pain differ from healthy cohorts in terms of global measures of strength? A systematic review and meta-analysis

Author

Enrico Verdini, Luca Maestroni, Michael Clark, Anthony Turner, and Jörg Huber

Subjects
Adult, Fibromyalgia, Musculoskeletal Pain, Rehabilitation, Humans, Female, Physical Therapy, Sports Therapy and Rehabilitation, Osteoarthritis, Knee, Low Back Pain
Abstract

Objective It is currently unknown if people with musculoskeletal pain display different multi-joint strength capacities than healthy cohorts. The aim was to investigate whether people with musculoskeletal pain show differences in global measures of strength in comparison to healthy cohorts. Data sources A systematic review was conducted using three databases (Medline, CINAHL and SPORTDiscus) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Review methods Studies involving participants with painful musculoskeletal conditions and multi-joint strength assessment measured at baseline were included. A meta-analysis was also performed to compute standardized mean differences (± 95% confidence intervals), using Hedge's g, and examined the differences in multi-joint strength at baseline between participants with painful musculoskeletal conditions and healthy participants. Results In total, 5043 articles were identified, of which 20 articles met the inclusion criteria and were included in the qualitative analysis. The available evidence revealed that multi-joint strength values were limited to knee osteoarthritis, fibromyalgia, chronic low back pain, and rheumatoid arthritis. Only four studies were included in the quantitative synthesis and revealed that only small differences in both chest press ( g = −0.34, 95% CI [−0.64, −0.03]) and leg press ( g = −0.25, 95% CI [−0.49, −0.02]) existed between adult women with fibromyalgia and active community women. Conclusion There is a paucity of multi-joint strength values in participants with musculoskeletal pain. Quantitative comparison with healthy cohorts was limited, except for those with fibromyalgia. Adult women with fibromyalgia displayed reduced multi-joint strength values in comparison to active community women.

Published
2022

120. TMEM219 regulates the transcription factor expression and proliferation of beta cells.

Author

D'Addio, Francesca, Assi, Emma, Maestroni, Anna, Rossi, Giada, Usuelli, Vera, Petrazzuolo, Adriana, Nardini, Marta, Loretelli, Cristian, Ben Nasr, Moufida, and Fiorina, Paolo

Subjects
PANCREATIC beta cells, ISLANDS of Langerhans, GENE expression, CELL proliferation, TRANSCRIPTION factors, TYPE 1 diabetes, CELL preservation
Abstract

Pancreatic beta cells replenishment is considered the next therapeutic option for type 1 diabetes; while stimulating endogenous beta cells proliferation is the "holy grail" for those patients with exhausted beta cell mass. Here we are demonstrating that the pro-apoptotic receptor TMEM219 is expressed in fetal pancreas, in beta cell precursors and in in vitro embryonic-derived endocrine progenitors. TMEM219 signaling negatively regulates beta cells at early stages and induces Caspase 8-mediated cell death. Pharmacological blockade of TMEM219 further rescued beta cell precursor and proliferation markers, and decreased cell death, both in islets and in in vitro-derived endocrine progenitors, allowing for beta cell preservation. While addressing the upstream controlling TMEM219 expression, we determined the TMEM219 miRNet; indeed, one of those miRNAs, miR-129-2, is highly expressed in human islets, particularly in patients at risk or with established type 1 diabetes. miR-129-2 mimic downregulated TMEM219 expression in islets, in in vitro embryonic-derived endocrine progenitors and in highly proliferating insulinoma-derived cells. Moreover, miR-129-2 inhibitor induced a TMEM219 overexpression in insulinoma-derived cells, which restored cell proliferation and functional markers, thus acting as endogenous regulator of TMEM219 expression. The TMEM219 upstream regulator miR129-2 controls the fate of beta cell precursors and may unleash their regenerative potentials to replenish beta cells in type 1 diabetes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

121. Role of Renal Biopsy in the Management of Renal Cancer: Concordance between Ultrasound/CT-Guided Biopsy Results and Definitive Pathology, Adverse Events, and Complication Rate.

Author

Isgrò, Gianmarco, Rogers, Alistair, Veeratterapillay, Rajan, Rix, David, Page, Toby, Maestroni, Umberto, Bertolotti, Lorenzo, Pagnini, Francesco, Martini, Chiara, De Filippo, Massimo, and Ziglioli, Francesco

Subjects
RENAL biopsy, RENAL cancer, COLD therapy, BIOPSY, RENAL cell carcinoma, PATHOLOGY
Abstract

(1) Background: In the last decade, the number of detected renal cancer cases has increased, with the highest incidence in Western countries. Although renal biopsy is reported as a safe procedure, it is not adopted in all centres. As it is not possible to accurately distinguish benign tumours using imaging, this may lead to overtreatment. Most of the cancer detected on imaging is treated by surgery, radiofrequency ablation (RFA), or cryotherapy. (2) Methods: This was a single-centre retrospective study of 225 patients studied preoperatively with ultrasound (US)/CT-guided renal biopsy, with the aim of supporting clinical management. Decisions regarding the biopsy were based on either MDT indication or physician preference. US-guided renal biopsy was the first option for all patients; CT-guided biopsy was used when US-guided biopsy was not feasible. The efficacy of renal biopsy in terms of diagnostic performance and the concordance between biopsy results and definitive pathology were investigated. Additionally, adverse events related to the biopsy were recorded and analysed. Data collected throughout the study were analysed using binary logistic regression, Fisher's exact test, and Pearson's chi-square test to investigate possible correlations between post-procedural complications and the size of the lesion. (3) Results: Renal biopsy was not diagnostic in 23/225 (10.2%) patients. A CT-guided approach was necessary in 20/225 patients after failure of US-guided biopsy. The complication rate of renal biopsy was 4.8% overall—all Clavien grade I and without any serious sequelae. Interestingly, complications occurred in patients with very different sizes of renal cell carcinoma. No correlation between complications and anticoagulant/antiplatelet drugs was found. No seeding was reported among the patients who underwent partial/radical nephrectomy. (4) Conclusions: Renal biopsy was shown to be safe and effective, with a high concordance between biopsy results and definitive pathology and a low rate of complications. The use of a CT-guided approach whenever the US-guided approach failed improved the diagnostic performance of renal biopsy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

124. List of Contributors

Author

de Andréa, Mara M., primary, Angel, Edwin Samir Barbosa, additional, Barreto, Fabiano, additional, Brena, Beatriz, additional, Cannavan, Andrew, additional, Carazo, Elizabeth, additional, Černi, Eduardo Egaña, additional, Alfaro, Pedro Enriquez, additional, Cesio, María Verónica, additional, Dallos, Jairo Arturo Guerrero, additional, Daguer, Heitor, additional, Franchi, Susana, additional, Gatti, Patricia, additional, Heinzen, Horacio, additional, Hernández, Julio Ernesto Payes, additional, Kohlmann, Bert, additional, Loewy, Ruth Miriam, additional, Luchini, Luiz Carlos, additional, Macchi, Pablo, additional, Maestroni, Britt, additional, Mora, Mario Alberto Masís, additional, Mora, Paula Aguilar, additional, Nario, Adriana, additional, Ochoa, Victoria, additional, Ohaco, Patricia, additional, Palma, Rodrigo, additional, Pampillo, Juan Salvador Chin, additional, Pappolla, Patricia, additional, Parada, Ana Maria, additional, Pareja, Lucia, additional, Perez, Andres, additional, Rodríguez, M. Alejandra, additional, Rodriguez, Mauricio, additional, Jacqueline Rojas, G., additional, Sánchez, Pablo, additional, Videla, Ximena, additional, and Vieira, Eliane, additional

Published
2019
Full Text
View/download PDF

126. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis

Author

DAddio, Francesca, Maestroni, Anna, Assi, Emma, Ben Nasr, Moufida, Amabile, Giovanni, Usuelli, Vera, Loretelli, Cristian, Bertuzzi, Federico, Antonioli, Barbara, Cardarelli, Francesco, El Essawy, Basset, Solini, Anna, Gerling, Ivan C., Bianchi, Cristina, Becchi, Gabriella, Mazzucchelli, Serena, Corradi, Domenico, Fadini, Gian Paolo, Foschi, Diego, Markmann, James F., Orsi, Emanuela, Skrha, Jan, Camboni, Maria Gabriella, Abdi, Reza, Shapiro, A. M. James, Folli, Franco, Ludvigsson, Johnny, Del Prato, Stefano, Zuccotti, Gianvincenzo, Fiorina, Paolo, D'Addio, F., Maestroni, A., Assi, E., Ben Nasr, M., Amabile, G., Usuelli, V., Loretelli, C., Bertuzzi, F., Antonioli, B., Cardarelli, F., El Essawy, B., Solini, A., Gerling, I. C., Bianchi, C., Becchi, G., Mazzucchelli, S., Corradi, D., Fadini, G. P., Foschi, D., Markmann, J. F., Orsi, E., Skrha, J., Camboni, M. G., Abdi, R., James Shapiro, A. M., Folli, F., Ludvigsson, J., Del Prato, S., Zuccotti, G., and Fiorina, P.

Subjects
Male, Cell- och molekylärbiologi, Inbred C57BL, cells, cultured, Transgenic, Mice, Mice, Inbred NOD, Insulin-Secreting Cells, middle aged, Homeostasis, animal, membrane protein, Cells, Cultured, Mice, Knockout, Cultured, Reverse Transcriptase Polymerase Chain Reaction, adult, gene expression regulation, Middle Aged, reverse transcriptase polymerase chain reaction, diabetes mellitus, type 1, female, diabetes mellitus, type 2, Female, immunoblotting, signal transduction, Type 2, Type 1, Signal Transduction, Adult, mice, inbred C57BL, Cells, Knockout, Science, mice, knockout, Immunoblotting, Mice, Transgenic, Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Insulin-Like Growth Factor Binding Protein 3, Membrane Proteins, Mice, Inbred C57BL, Gene Expression Regulation, male, insulin-secreting cell, Diabetes Mellitus, human, mice, inbred NOD, mice, transgenic, homeostasi, Settore FIS/07 - Fisica Applicata(Beni Culturali, Ambientali, Biol.e Medicin), Inbred NOD, insulin-like growth factor binding protein 3, Cell and Molecular Biology
Abstract

In this new study the Authors demonstrated that the IGFBP3/TMEM219 pathway is a physiological regulator of pancreatic beta cell homeostasis and it is dysregulated in diabetes. IGFBP3/TMEM219 targeting may therefore serve as a therapeutic option in diabetes. Loss of pancreatic beta cells is a central feature of type 1 (T1D) and type 2 (T2D) diabetes, but a therapeutic strategy to preserve beta cell mass remains to be established. Here we show that the death receptor TMEM219 is expressed on pancreatic beta cells and that signaling through its ligand insulin-like growth factor binding protein 3 (IGFBP3) leads to beta cell loss and dysfunction. Increased peripheral IGFBP3 was observed in established and at-risk T1D/T2D patients and was confirmed in T1D/T2D preclinical models, suggesting that dysfunctional IGFBP3/TMEM219 signaling is associated with abnormalities in beta cells homeostasis. In vitro and in vivo short-term IGFBP3/TMEM219 inhibition and TMEM219 genetic ablation preserved beta cells and prevented/delayed diabetes onset, while long-term IGFBP3/TMEM219 blockade allowed for beta cell expansion. Interestingly, in several patients cohorts restoration of appropriate IGFBP3 levels was associated with improved beta cell function. The IGFBP3/TMEM219 pathway is thus shown to be a physiological regulator of beta cell homeostasis and is also demonstrated to be disrupted in T1D/T2D. IGFBP3/TMEM219 targeting may therefore serve as a therapeutic option in diabetes. Funding Agencies|SID Lombardia Grant; EFSD/JDRF/Lilly Programme on Type 1 Diabetes Research; Italian Ministry of HealthMinistry of Health, Italy [RF-2016-02362512]; Universita di Milano; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK104155]; Juvenile Diabetes Research FoundationJuvenile Diabetes Research Foundation; Enthera S.r.l.

Published
2022

127. TACKLING THE CHALLENGE OF BIO-BASED PRODUCTIONS BY LEVERAGING THE POTENTIAL OF YEAST BIODIVERSITY AND SYNTHETIC BIOLOGY

Author

MAESTRONI, LETIZIA, Maestroni, L, and BRANDUARDI, PAOLA

Subjects
L. starkeyi, residual bioma, S. cerevisiae, Yeast cell factory, BIO/11 - BIOLOGIA MOLECOLARE, Biomasse residuali, Synthetic biology, Biologia sintetica
Abstract

Il ruolo principale delle biotecnologie industriali è quello di fornire soluzioni innovative per alcune delle più grandi sfide del mondo. Nonostante il potenziale e le tecniche innovative applicate, i processi microbiologici bio-based necessitano ancora di ulteriori studi per diventare pervasivi e quindi sostituire i processi di produzione tradizionali. Per rendere i processi microbici economicamente fattibili e rispettosi dell'ambiente, uno dei fattori chiave risiede nella scelta della biomassa di partenza. In una logica di bioeconomia circolare, i sottoprodotti e le biomasse residue devono essere considerati come materie prime di partenza del processo. L'uso di queste biomasse non solleva questioni etiche e allo stesso tempo è economicamente vantaggioso e orientato all'ambiente. La maggior parte di queste biomasse residue sono residui agricoli e forestali, una famiglia di biomasse caratterizzate da una struttura lignocellulosica. Il problema legato al loro utilizzo nelle bioraffinerie a base microbica è quello di trovare un pretrattamento efficiente per convertirli in zuccheri fermentabili e altri nutrienti, riducendo al minimo il rilascio di inibitori della crescita microbica. Parlando di bioraffinerie microbiche, ci sono due aspetti principali da tenere a mente durante la progettazione del processo: la biomassa di partenza e l'ospite microbico. L’host finale può essere scelto seguendo due approcci complementari: i) sfruttare la biodiversità microbica già presente in natura, scegliendo l'ospite finale in base alle sue caratteristiche innate, particolarmente vantaggiose in uno specifico processo produttivo; ii) lavorare su una cell factory già nota, customizzandola secondo le necessità. Nel Capitolo 2 è stata valutata una specifica classe di lieviti non convenzionali, denominata lieviti oleaginosi, per ottenere oli microbici (SCOs) per la produzione di biodiesel a partire da scarti dell'industria della barbabietola da zucchero. Lipomyces starkeyi è stato selezionato come cell factory per la conversione della polpa di barbabietola da zucchero e della melassa di barbabietola da zucchero per massimizzare l'accumulo di SCOs. Con questo esempio applicativo abbiamo dimostrato la possibilità di sfruttare microrganismi non convenzionali per ottenere bio-carburanti più sostenibili. D'altra parte, la scelta di Saccharomyces cerevisiae come ospite finale ha il grande vantaggio di sfruttare l'ampia conoscenza che lo circonda, compreso l’enorme numero di approcci di biologia sintetica per disegnarlo nella forma finale necessaria. Nel Capitolo 3 presento una nuova combinazione di approcci di biologia sintetica per accelerare le procedure di ingegnerizzazione, consentendo l’over-espressione e lo studio di vie biosintetiche eterologhe sempre più complesse. Inoltre, mostro l'applicazione di questo nuovo kit di strumenti alla produzione di un metabolita secondario di pianta. Nel capitolo 4 descrivo la progettazione di un nuovo vettore per migliorare le procedure di editing del genoma in S. cerevisiae. Anche in questo secondo progetto l'obiettivo finale è stato quello di velocizzare le fasi di progettazione e costruzione e le procedure di laboratorio, standardizzandole il più possibile per semplificare una parte del lavoro e lasciare più spazio alle fasi successive di test & learn. Nel Capitolo 5 propongo il concetto di co-localizzazione spaziale degli enzimi come campo d'avanguardia nella biologia sintetica per massimizzare il flusso di carbonio verso il prodotto di interesse, sfruttando l'uso di scaffold proteici sintetici e domini di interazione sintetici. La tesi qui presentata vuole porsi come esempio pratico di come le biotecnologie industriali possano essere utilizzate come potente strumento nella difficile transizione da una società basata sul petrolio e una più sostenibile. The role of industrial biotechnology is to provide game-changing solutions for some of the world’s greatest challenges. From climate change to alternative energy sources and to sustainable productions, industrial biotechnology is fighting to find new sustainable solutions. Despite the promising potential and the innovative techniques applied, bio-based biological processes still need further studies for becoming pervasive and therefore substituting the traditional processes of production. To make microbial processes economically feasible and environmentally friendly, one of the key factors resides in the choice of the starting biomass. In a logic of circular bioeconomy, by-products and residual biomasses have to be considered as starting feedstocks of the process. The use of these biomasses does not raise ethical issues and at the same time is economically advantageous and environment oriented. Indeed, they do not compete with the food industry, as they are usually production waste. Most of these residual biomasses are agricultural and forest residues, a family of biomasses characterised by a lignocellulosic structure. The problem related to their use in microbial-based biorefineries is to find an efficient pretreatment to convert them into fermentable sugars and other nutrients, while reducing to a minimum the release of inhibitors of microbial growth. Talking about microbial-based biorefinery as a substitute to petrol-based refinery, there are two main topics to keep in mind during the process design: the starting biomass and the microbial host. The chassis which will be involved in the final production process can be chosen following two complementary approaches: i) exploiting microbial biodiversity already present in nature by picking the final host depending on its innate characteristics, particularly advantageous in a specific production process; ii) working on a well-known cell factory by customising it as needed. In this thesis both principles were followed. In Chapter 2 a specific class of non-conventional yeasts, named oleaginous yeasts, was evaluated to obtain single cell oils (SCOs) for biodiesel production starting from wastes of the sugar beet industry. Lipomyces starkeyi was selected as cell factory for the conversion of sugar beet pulp and sugar beet molasses to maximise SCOs accumulation. With this applicative example we showed the possibility to take advantage of non-conventional microorganisms to achieve a more sustainable way to produce fuels. On the other hand, choosing Saccharomyces cerevisiae as final host has the major advantage of exploiting the wide knowledge around it, starting from its genome and physiology, and arriving at the tremendous number of synthetic biology approaches to engineer it and manipulate it in the desired final form. In Chapter 3 I introduce a novel toolkit: a new combination of synthetic biology approaches to accelerate the engineering procedures allowing the overexpression and the study of more and more complex biosynthetic heterologous pathways. Moreover, I show the application of this novel toolkit to the production of a selected plant secondary metabolite. In Chapter 4 I describe the design of a new vector to improve genome editing procedures in S. cerevisiae. Even in this second project the final goal was to speed up the design and build stages and laboratory procedures, standardising them as much as possible to simplify one part of scientists' work, to leave more space to the subsequent phases of testing and learning. In Chapter 5 I propose the concept of enzyme spatial co-localisation as a forefront field in synthetic biology to maximise the carbon flux toward the product of interest, exploiting the use of protein synthetic scaffolds and synthetic interaction domains. The presented thesis wants to pose itself as a practical example on how industrial biotechnology can be used as a powerful tool in the difficult transition to a more sustainable society.

Published
2023

129. P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes

Author

D'Addio, Francesca, Vergani, Andrea, Potena, Luciano, Maestroni, Anna, Usuelli, Vera, Nasr, Moufida Ben, Bassi, Roberto, Tezza, Sara, Dellepiane, Sergio, Essawy, Basset El, Iascone, Maria, Iacovoni, Attilio, Borgese, Laura, Liu, Kaifeng, Visner, Gary, Dhe-Paganon, Sirano, Corradi, Domenico, Abdi, Reza, Starling, Randall C., Folli, Franco, Zuccotti, Gian Vincenzo, Sayegh, Mohamed H., Heeger, Peter S., Chandraker, Anil, Grigioni, Francesco, and Fiorina, Paolo

Subjects
Heart transplantation -- Usage -- Complications and side effects, Gene mutation -- Research, Cardiac patients -- Health aspects, Transcription factors -- Analysis, T cells -- Research, Health care industry
Abstract

Purinergic receptor-7 (P2X7R) signaling controls Th17 and Th1 generation/differentiation, while NOD-like receptor P3 (NLRP3) acts as a Th2 transcriptional factor. Here, we demonstrated the existence of a P2X7R/NLRP3 pathway in T cells that is dysregulated by a P2X7R intracellular region loss-of-function mutation, leading to NLRP3 displacement and to excessive Th17 generation due to abrogation of the NLRP3-mediated Th2 program. This ultimately resulted in poor outcomes in cardiac-transplanted patients carrying the mutant allele, who showed abnormal Th17 generation. Transient NLRP3 silencing in nonmutant T cells or overexpression in mutant T cells normalized the Th profile. Interestingly, IL-17 blockade reduced Th17 skewing of human T cells in vitro and abrogated the severe allograft vasculopathy and abnormal Th17 generation observed in preclinical models in which P2X7R was genetically deleted. This P2X7R intracellular region mutation thus impaired the modulatory effects of P2X7R on NLRP3 expression and function in T cells and led to NLRP3 dysregulation and Th17 skewing, delineating a high-risk group of cardiac-transplanted patients who may benefit from personalized therapy., Introduction Purinergic receptor-7 (P2X7R), primarily expressed on lymphocytes, senses adenosine 5'-triphosphate (ATP) (1) released extracellularly during cell damage (2, 3) and has been shown to regulate T cell activation (4-6). [...]

Published
2018
Full Text
View/download PDF

134. Eroded telomeres are rearranged in quiescent fission yeast cells through duplications of subtelomeric sequences

Author

Laetitia Maestroni, Julien Audry, Samah Matmati, Benoit Arcangioli, Vincent Géli, and Stéphane Coulon

Subjects
Science
Abstract

How both telomere stability is regulated and dysfunctional telomeres processed in quiescent cells is poorly understood. Here, the authors provide evidence that eroded telomeres in quiescent fission yeast are rearranged by homologous recombination through duplications of subtelomeric sequences.

Published
2017
Full Text
View/download PDF

135. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two

Author

Olga Lomakina, Ekaterina Alekseeva, Sania Valieva, Tatiana Bzarova, Irina Nikishina, Elena Zholobova, Svetlana Rodionovskaya, Maria Kaleda, Yasuo Nakagishi, Masaki Shimizu, Mao Mizuta, Akihiro Yachie, Yuko Sugita, Nami Okamoto, Kousuke Shabana, Takuji Murata, Hiroshi Tamai, Eve M. Smith, Peng Yin, Andrea L. Jorgensen, Michael W. Beresford, on behalf of On behalf of the UK JSLE Cohort Study, Antonio Eleuteri, Beatrice Goilav, Laura Lewandowski, Angel Phuti, Dawn Wahezi, Tamar Rubinstein, Caroline Jones, Paul Newland, Stephen Marks, Rachel Corkhill, Diana Ekdawy, Clarissa Pilkington, Kjell Tullus, Chaim Putterman, Chris Scott, Antony C. Fisher, Andrea Jorgensen, Ezgi Deniz Batu, Can Kosukcu, Ekim Taskiran, Sema Akman, Kubra Ozturk, Betul Sozeri, Erbil Unsal, Zelal Ekinci, Yelda Bilginer, Mehmet Alikasifoglu, Seza Ozen, Hanna Lythgoe, Hermine I. Brunner, Gaurav Gulati, Jordan T. Jones, Mekibib Altaye, Jamie Eaton, Mark Difrancesco, Joo Guan Yeo, Jingyao Leong, Loshinidevi D/O Thana Bathi, Thaschawee Arkachaisri, Salvatore Albani, Nagla Abdelrahman, Michael W Beresford, Valentina Leone, UK JSLE study group supported by the National Institute of Health Research Clinical Research Network, Noortje Groot, D. Shaikhani, I. E. M. Bultink, M. Bijl, R. J. E. M. Dolhain, Y. K. O. Teng, E. Zirkzee, K. de Leeuw, R. Fritsch-Stork, S. S. M. Kamphuis, Rachael D. Wright, Reem Abdawani, Laila Al Shaqshi, Ibrahim Al Zakwani, Natali W. Gormezano, David Kern, Oriany L. Pereira, Gladys C. C. Esteves, Adriana M. Sallum, Nadia E. Aikawa, Rosa M. Pereira, Clovis A. Silva, Eloisa Bonfa, Jessica Beckmann, Nora Bartholomä, Nils Venhoff, Philipp Henneke, Ulrich Salzer, Ales Janda, Alina Lucica Boteanu, Sandra Garrote Corral, Alberto Sifuentes Giraldo, Mariluz Gámir Gámir, Antonio Zea Mendoza, Amra Adrovic, Reyhan Dedeoglu, Sezgin Sahin, Kenan Barut, Aida Koka, Funda Oztunc, Ozgur Kasapcopur, Ana Luisa Rodriguez-Lozano, Francisco Rivas-Larrauri, Silvestre García de la Puente, Andressa G. F. Alves, Maria F. D. A. Giacomin, Juliana Farhat, Alfésio L. F. Braga, Adriana M. E. Sallum, Lúcia M. D. A. Campos, Luiz A. A. Pereira, Ana J. D. F. C. Lichtenfels, Clóvis A. Silva, Sylvia C. L. Farhat, Banu Acar, Z. Birsin Ozcakar, Nilgün Çakar, Nermin Uncu, Gökçe Gür, Semanur Özdel, Fatoş Yalçınkaya, Christiaan Scott, Nicky Brice, Peter Nourse, Christine Arango, Angela C. Mosquera, Clara Malagon, Ana P. Sakamoto, Marco F. C. D. Silva, Ananadreia S. Lopes, Gleice C. S. Russo, Adriana E. M. Sallum, Katia Kozu, Eloisa Bonfá, Claudia Saad-Magalhães, Rosa M. R. Pereira, Claudio A. Len, Maria T. Terreri, Deepti Suri, Siyaram Didel, Amit Rawat, Surjit Singh, Despoina Maritsi, MArgarita Onoufriou, Olga Vougiouka, Maria Tsolia, Edi Paleka Bosak, Mandica Vidović, Mirta Lamot, Lovro Lamot, Miroslav Harjaček, Erika Van Nieuwenhove, Adrian Liston, Carine Wouters, Fatemeh Tahghighi, Vahid Ziaee, Seid-Reza Raeeskarami, Francisca Aguiar, Sandra Pereira, Mariana Rodrigues, Cláudia Moura, Gustavo Rocha, Hercília Guimarães, Iva Brito, Rita Fonseca, Gerd Horneff, Ariane Klein, Kirsten Minden, Hans-Iko Huppertz, Frank Weller-Heinemann, Jasmin Kuemmerle-Deschner, J-Peter Haas, Anton Hospach, BIKER collaborative group, Ricardo Menendez-Castro, Boris Huegle, Johannes-Peter Haas, Joost Swart, Gabriella Giancane, Francesca Bovis, Elio Castagnola, Andreas Groll, Daniel J. Lovell, Tom Wolfs, Michael Hofer, Violeta Panaviene, Susan Nielsen, Jordi Anton, Florence Uettwiller, Valda Stanevicha, Maria Trachana, Denise Pires Marafon, Constantin Ailioaie, Elena Tsitsami, Sylvia Kamphuis, Troels Herlin, Pavla Doležalová, Gordana Susic, Berit Flatø, Flavio Sztajnbok, Angela Pistorio, Alberto Martini, Nico Wulffraat, Nicolino Ruperto, Marco Gattorno, Antonio Brucato, Martina Finetti, George Lazaros, Silvia Maestroni, Mara Carraro, Davide Cumetti, Alessandra Carobbio, Monia Lorini, Alessandro Rimini, Renzo Marcolongo, Anna Valenti, Gian Luca Erre, Riccardo Belli, Fiorenzo Gaita, Maria Pia Sormani, Massimo Imazio, Mario Abinun, Nicola Smith, Tim Rapley, Flora McErlane, Lianne Kearsley-Fleet, Kimme L. Hyrich, Helen Foster, Nikolay Tzaribachev, Andrew Zeft, Rolando Cimaz, John Bohnsack, Thomas Griffin, Ruy Carrasco, Jason Dare, Ivan Foeldvari, Richard Vehe, Teresa Simon, Hermine Brunner, S. Verazza, S. Davì, A. Consolaro, A. Insalaco, V. Gerloni, R. Cimaz, F. Zulian, S. Pastore, F. Corona, G. Conti, P. Barone, M. Cattalini, E. Cortis, L. Breda, A. N. Olivieri, A. Civino, R. Podda, D. Rigante, F. La Torre, G. D’Angelo, M. Jorini, R. Gallizzi, M. C. Maggio, R. Consolini, A. De Fanti, M. G. Alpigiani, A. Martini, A. Ravelli, on behalf of Italian Pediatric Rheumatology Study Group, Aysenur Pac Kısaarslan, Zubeyde Gunduz, Ruhan Dusunsel, Ismail Dursun, Hakan Poyrazoglu, Ekaterina Kuchinskaya, Farida Abduragimova, Mikhail Kostik, Erik Sundberg, Soley Omarsdottir, Lena Klevenvall, Helena Erlandsson-Harris, Gokalp Basbozkurt, Ozge Erdemli, Dogan Simsek, Fatih Yazici, Yildirim Karsioglu, Aysen Tezcaner, Dilek Keskin, Huseyin Ozkan, Cengizhan Acikel, Erkan Demirkaya, Ilonka Orbán, Krisztina Sevcic, Valentin Brodszky, Emese Kiss, Ismaiel A. Tekko, Madeleine Rooney, James McElnay, Cliff Taggart, Helen McCarthy, Ryan F. Donnelly, Drug Delivery Group, Mary Slatter, Zohreh Nademi, Mark Friswell, Sharmila Jandial, Terence Flood, Sophie Hambleton, Andrew Gennery, Andrew Cant, Phoi-Ngoc Duong, Isabelle Koné-Paut, Giovanni Filocamo, María Luz Gamir, Helga Sanner, Laura Carenini, Mesut Topdemir, Yildirim Karslioglu, Faysal Gok, Nadezhda Tsurikova, Elena Ligostaeva, Navdha R. Ramchurn, O. Kostareva, I. Nikishina, S. Arsenyeva, S. Rodionovskaya, M. Kaleda, D. Alexeev, Ismail Dursun Dursun, Sara Murias, Estefania Barral, Rosa Alcobendas, Eugenia Enriquez, Agustin Remesal, Jaime de Inocencio, Tania M. Castro, Simone A. Lotufo, Tatjana Freye, Raffaella Carlomagno, Thomas Zumbrunn, Jan Bonhoeffer, Elvira Cannizzaro Schneider, Daniela Kaiser, Michaël Hofer, Véronique Hentgen, Andreas Woerner, Juvenile Inflammatory Rheumatism (JIR) Cohort, Tobias Schwarz, Jens Klotsche, Martina Niewerth, Gerd Ganser, ICON study group, Jerold Jeyaratnam, Nienke ter Haar, Donato Rigante, Fatma Dedeoglu, Ezgi Baris, Sebastiaan Vastert, Joost Frenkel, Jonathan S. Hausmann, Kathleen G. Lomax, Ari Shapiro, Karen L. Durrant, P. A. Brogan, M. Hofer, J. B. Kuemmerle-Deschner, B. Lauwerys, A. Speziale, K. Leon, X. Wei, R. M. Laxer, Sara Signa, Marta Rusmini, Elena Campione, Sabrina Chiesa, Alice Grossi, Alessia Omenetti, Roberta Caorsi, Gianmaria Viglizzo, Isabella Ceccherini, Silvia Federici, Helen Lachmann, Nicola Ruperto, on behalf of PRINTO and Eurofever Registry, Federica Vanoni, on behalf of PRINTO and Eurofever Project, Sonia Melo Gomes, Ebun Omoyinmi, Juan I. Arostegui, Eva Gonzalez-Roca, Despina Eleftheriou, Nigel Klein, Paul Brogan, Stefano Volpi, Elettra Santori, Paolo Picco, Claudia Pastorino, Gillian Rice, Alessandra Tesser, Yanick Crow, Fabio Candotti, Ada B. Sinoplu, Gozde Yucel, Gizem Pamuk, Laura O. Damian, Cecilia Lazea, Mihaela Sparchez, Paulina Vele, Laura Muntean, Adriana Albu, Simona Rednic, Calin Lazar, Leonardo O. Mendonça, Alessandra Pontillo, Jorge Kalil, Fabio M. Castro, Myrthes T. Barros, Manuela Pardeo, Virginia Messia, Fabrizio De Benedetti, Antonella Insalaco, Giorgia Malighetti, Chiara Gorio, Francesca Ricci, Ilaria Parissenti, Paola Montesano, Barbara Bonafini, Veronica Medeghini, Marco Cattalini, Lucio Giordano, Giulia Zani, Rosalba Ferraro, Donatella Vairo, Silvia Giliani, Maria Cristina Maggio, Girolamo Luppino, Giovanni Corsello, Maria Isabel Gonzalez Fernandez, Berta Lopez Montesinos, Adriana Rodriguez Vidal, Juan I. Arostegui Gorospe, Inmaculada Calvo Penades, Nadia K. Rafiq, Karen Wynne, Khalid Hussain, Paul A. Brogan, Elizabeth Ang, Nicholas Ng, Ayla Kacar, Ozge Altug Gucenmez, Balahan Makay, Sevket Erbil Unsal, Yasin Sahin, Tufan Kutlu, Fugen Cullu-Cokugras, Hasret Ayyildiz-Civan, Tulay Erkan, Sana Al Zuhbi, Eiman Abdalla, Ricardo A. Russo, María M. Katsicas, Francesca Minoia, Angelo Ravelli, Sagar Bhattad, Anju Gupta, Vignesh Pandiarajan, Ritambhra Nada, Kaara Tiewsoh, Philip Hawkins, Dorota Rowczenio, Sarka Fingerhutova, Jana Franova, Leona Prochazkova, Eva Hlavackova, Pavla Dolezalova, Havva Evrengül, Selçuk Yüksel, Mustafa Doğan, Dolunay Gürses, Harun Evrengül, Silvia De Pauli, Serena Pastore, Anna Monica Bianco, Giovanni Maria Severini, Andrea Taddio, Alberto Tommasini, Svetlana O. Salugina, Evgeny Fedorov, Elena Kamenets, Ekaterina Zaharova, Tatiana Sleptsova, Ekaterina Alexeeva, Kirill Savostyanov, Alexander Pushkov, Tatyana Bzarova, Saniya Valieva, Rina Denisova, Kseniya Isayeva, Evgeniya Chistyakova, Margarita Soloshenko, Elena Kaschenko, Utako Kaneko, Chihaya Imai, Akihiko Saitoh, Vitor A. Teixeira, Filipa O. Ramos, Manuela Costa, Yonatan Butbul Aviel, Shafe Fahoum, Riva Brik, Zeynep Birsin Özçakar, Banu Acar Celikel, Fatos Yalcinkaya, Benedetta Schiappapietra, Sergio Davi’, Federica Mongini, Luisa Giannone, Cecilia Bava, Maria Giannina Alpigiani, Alessandro Consolaro, Dragana S. Lazarevic, Jelena Vojinovic, Jelena Basic, Valentina Muratore, Valentina Marzetti, Neus Quilis, Belen Serrano Benavente, Alessandra Alongi, Adele Civino, Lorenzo Quartulli, Giedre Januskeviciute, Pieter van Dijkhuizen, N. Groot, W. van Dijk, A. Kardolus, Raul Gutiérrez Suárez, Ellen B. Nordal, Veronika G. Rypdal, Lillemor Berntson, Maria Ekelund, Kristiina Aalto, Suvi Peltoniemi, Marek Zak, Mia Glerup, Ellen D. Arnstad, Anders Fasth, Marite Rygg, the Nordic Study Group of Pediatric Rheumatology (NoSPeR), Ana Catarina Duarte, Sandra Sousa, Lídia Teixeira, Ana Cordeiro, Mª José Santos, Ana Filipa Mourão, Maria José Santos, Mónica Eusébio, Ana Lopes, Filipa Oliveira-Ramos, Manuel Salgado, Paula Estanqueiro, José Melo-Gomes, Fernando Martins, José Costa, Carolina Furtado, Ricardo Figueira, Jaime C. Branco, João E. Fonseca, Helena Canhão, Ana F. Mourão, Maria Jose Santos, Andrea Coda, Samuel Cassidy, Kerry West, Gordon Hendry, Debra Grech, Julie Jones, Fiona Hawke, Davinder Singh Grewal, Charlene Foley, Orla Killeen, Emma MacDermott, Douglas Veale, Ursula Fearon, Dilek Konukbay, Ela Tarakci, Nilay Arman, Sezgin Şahin, Jane Munro, Esi Morgan, Meredith Riebschleger, Jennifer Horonjeff, Vibeke Strand, Clifton Bingham, Ma. Theresa M. Collante, Margarita Ganeva, Stefan Stefanov, Albena Telcharova, Dimitrina Mihaylova, Radoslava Saraeva, Reni Tzveova, Radka Kaneva, Adelina Tsakova, Katya Temelkova, GRANT Medical University, Sofia 68/, Maria Mercedes C. Picarelli, Luiz C. Danzmann, Florencia Barbé-Tuana, Lucas K. Grun, Marcus H. Jones, Marijan Frković, Karla Ištuk, Ika Birkić, Saša Sršen, Marija Jelušić, Alan Easton, Rachael Quarmby, Raju Khubchandani, Mercedes Chan, Radoslav Srp, Katerina Kobrova, Dana Nemcova, Jozef Hoza, Michal Uher, Melania Saifridova, Lenka Linkova, Sirirat Charuvanij, Isree Leelayuwattanakul, Thita Pacharapakornpong, Sakda A.-O. Vallipakorn, Butsabong Lerkvaleekul, Soamarat Vilaiyuk, Stefano Lanni, Sergio Davì, Randy Q. Cron, Chiara Passarelli, Elisa Pisaneschi, Antonio Novelli, Claudia Bracaglia, Ivan Caiello, Kathy de Graaf, Florence Guilhot, Walter Ferlin, Grant Schulert, Alexi A. Grom, Robert Nelson, Cristina de Min, Dirk Holzinger, Christoph Kessel, Ndate Fall, Alexei Grom, Wilco de Jager, Raffaele Strippoli, Anna Horne, Stephan Ehl, Sandra Ammann, Kai Lehmberg, Karin Beutel, Dirk Foell, AnnaCarin Horne, Laura Pagani, Graciela Espada, Yi-jin Gao, Susan Shenoi, Sheila Weitzman, Giusi Prencipe, Antonia Pascarella, Walter G. Ferlin, Laurence Chatel, Philippe Jacqmin, Kathy De Graaf, Maria Ballabio, Zoë Johnson, Geneviève Lapeyre, Fabrizio de Benedetti, de Min Cristina, Hiroyuki Wakiguchi, Shunji Hasegawa, Reiji Hirano, Fumiko Okazaki, Tamaki Nakamura, Hidenobu Kaneyasu, Shouichi Ohga, Kazuko Yamazaki, Tomo Nozawa, Taichi Kanetaka, Shuichi Ito, Shumpei Yokota, Kirsty McLellan, Ishbel MacGregor, Neil Martin, Joyce Davidson, Sandra Hansmann, Andreas Eikelberg, Iris Haug, Sabrina Schuller, Susanne M. Benseler, Single Hub and Access point for paediatric Rheumatology in Europe (SHARE), Liliia S. Nazarova, Kseniia V. Danilko, Viktor A. Malievsky, Tatiana V. Viktorova, Angela Mauro, Angela Barnicoat, Jane Hurst, Nathalie Canham, Sandrine Lacassagne, Anastasia Wiener, Boris Hügle, Bernd Denecke, Ivan Costa-Filho, Johannes Peter Haas, Klaus Tenbrock, David Popp, Arjan Boltjes, Frank Rühle, Stefanie Herresthal, Femke van Wijk, Joachim Schultze, Monika Stoll, Luisa Klotz, Thomas Vogl, Johannes Roth, Estefania Quesada-Masachs, Daniel Álvarez de la Sierra, Marina Garcia Prat, Ana M. Marín Sánchez, Ricardo Pujol Borrell, Sara Marsal Barril, Mónica Martínez Gallo, Consuelo Modesto Caballero, Iryna Chyzheuskaya, Lyudmyla M. Byelyaeva, Rostislav M. Filonovich, Helena K. Khrustaleva, Larisa I. Zajtseva, Tamara M. Yuraga, Thomas Giner, Lukas Hackl, Julia Albrecht, Reinhard Würzner, Juergen Brunner, Marta Minute, Fulvio Parentin, Agostino Nocerino, Mette Nørgaard, Mikel Alberdi-Saugstrup, Marek S. Zak, Susan M. Nielsen, Ellen Nordal, Klaus G. Müller, Nordic Study Group of Pediatric Rheumatology (NoSPeR), Mojca Zajc Avramovič, Vita Dolžan, Nataša Toplak, Tadej Avčin, N. Ruperto, D. J. Lovell, C. Wallace, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, C. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. M. Kuester, J. Dare, M. Heinrich, H. Kupper, J. Kalabic, H. I. Brunner, on behalf of PRINTO and PRCSG, Ruben Burgos-Vargas, Tamas Constantin, Joke Dehoorne, Valda Stanevica, Katarzyna Kobusinska, Zbigniew Zuber, Richard Mouy, Ingrida Rumba-Rozenfelde, Chantal Job-Deslandre, Ronald Pederson, Jack Bukowski, Tina Hinnershitz, Bonnie Vlahos, Paula Keskitalo, Salla Kangas, Paula Vähäsalo, Raul A. Chavez Valencia, David Martino, Anne-Louise Ponsonby, Rachel Chiaroni-Clarke, Braydon Meyer, Roger C. Allen, Jonathan D. Akikusa, Jeffrey M. Craig, Richard Saffrey, Justine A. Ellis, Carol Wallace, Yosef Uziel, Gary Sterba, Rayfel Schneider, Ricardo Russo, Athimalaipet V. Ramanan, Jana Pachlopnik Schmid, Kim E Nichols, Paivi Miettunen, Toshiyuki Kitoh, Norman T. Ilowite, Jan-Inge Henter, Alexei A Grom, Edward M. Behrens, Tadej Avcin, Maurizio Aricò, Sriharsha Grevich, Peggy Lee, Sarah Ringold, Brian Leroux, Hannah Leahey, Megan Yuasa, Jessica Foster, Jeremy Sokolove, Lauren Lahey, William Robinson, Joshua Newson, Anne Stevens, Stephanie J. W. Shoop, Suzanne M. M. Verstappen, Wendy Thomson, Janet E. McDonagh, CAPS, Timothy Beukelman, Yuki Kimura, Marc Natter, Norm Ilowite, Kelly Mieszkalski, Grendel Burrell, Brian Best, Helen Bristow, Shannon Carr, Anne Dennos, Rachel Kaufmann, Laura Schanberg, for the CARRA Registry Investigators, Gabriele Simonini, Francesca Lancini, Margaux Gerbaux, Phu-Quoc Lê, Laurence Goffin, Valérie Badot, Céline La, Laure Caspers, François Willermain, Alina Ferster, Maria Ceci, Francesco Licciardi, Marco Turco, Francesca Santarelli, Davide Montin, Claudia Toppino, Clotilde Alizzi, Bruno Papia, Beatrice Vergara, Umberto Corpora, Luca Messina, Maria Tsinti, Vasiliko Dermentzoglou, Panagiotis Tziavas, Marija Perica, Lana Tambić Bukovac, Mustafa Çakan, Nuray Aktay Ayaz, Gonca Keskindemirci, Michael Lang, Catherine Laing, Susanne Benseler, Tommy Gerschman, Nadia Luca, Heinrike Schmeling, Anastasia Dropol, Jaymi Taiani, Nicole Johnson, Brian Rusted, Panagiota Nalbanti, Polyxeni Pratsidou, Grigoris Pardalos, Vasiliki Tzimouli, Anna Taparkou, Maria Stavrakidou, Fotios Papachristou, Florence Kanakoudi-Tsakalidou, Peter Bale, Emily Robinson, Jason Palman, Elizabeth Ralph, Kimberly Gilmour, Clare Heard, Lucy R. Wedderburn, Yara Barrense-Dias, Antonarakis Gregory, Dhouib Amira, Scolozzi Paolo, Hanquinet Sylviane, Hofer Michaël, Nataliya Panko, Salah Shokry, Liudmila Rakovska, Sally Pino, Adriana Diaz-Maldonado, Pilar Guarnizo, Sofia Torreggiani, Paolo Cressoni, Umberto Garagiola, Giancarla Di Landro, Giampietro Farronato, Fabrizia Corona, Samantha Bell, Parveen Bhatti, Lee Nelson, Beth A. Mueller, T. A. Simon, A. Baheti, N. Ray, Z. Guo, Anasuya Hazra, Thomas Stock, Ronnie Wang, Charles Mebus, Christine Alvey, Manisha Lamba, Sriram Krishnaswami, Umberto Conte, Min Wang, Daniel Kingsbury, Elena Koskova, Elzbieta Smolewska, Richard K. Vehe, Daniel Lovell, Tomohiro Kubota, Junko Yasumura, Toshitaka Kizawa, Masato Yashiro, Tsuyoshi Yamatou, Yuichi Yamasaki, Syuji Takei, Yoshifumi Kawano, Ulrika Järpemo Nykvist, Bo Magnusson, Rikard Wicksell, Karin Palmblad, Gunnar L. Olsson, Mohammadreza Modaressi, Mohammad-Hassan Moradinejad, Valentina Seraya, Alisa Vitebskaya, Veronica Moshe, Gil Amarilyo, Liora Harel, Phillip J Hashkes, Amir Mendelson, Noa Rabinowicz, Yonit Reis, Zane Dāvidsone, Arina Lazareva, Ruta Šantere, Dace Bērziņa, Valda Staņēviča, Giulia Camilla Varnier, Susan Maillard, Cristina Ferrari, Silvia Zaffarano, Juvenile Dermatomyositis Research Group and European Federation of Immunological Societies, Judith Wienke, Felicitas Bellutti Enders, Lucas L. van den Hoogen, Jorre S. Mertens, Timothy R. Radstake, Henny G. Hotten, Ruth Fritsch, Lucy Wedderburn, Kiran Nistala, Berent Prakken, Annet van Royen-Kerkhof, Mohammad Alhemairi, Mohammed Muzaffer, Pieter Van Dijkhuizen, Claire T. Deakin, Stefania Simou, Maria De Iorio, Qiong Wu, Tania Amin, Lee Dossetter, Juvenile Dermatomyositis Research Group (JDRG), Raquel Campanilho-Marques, Claire Deakin, Clarissa A. Pilkington, on behalf of Juvenile Dermatomyositis Research Group (JDRG), Silvia Rosina, Sirisucha Soponkanaporn, on behalf of the UK Juvenile Dermatomyositis Research Group (JDRG), Zehra S. Arıcı, Gökçen D. Tuğcu, Ezgi D. Batu, Hafize E. Sönmez, Deniz Doğru-Ersöz, Beril Talim, Nural Kiper, Seza Özen, Alexander Solyom, Ezgi Batu, John Mitchell, Ariana Kariminejad, Fatemeh Hadipour, Zahra Hadipour, Marta Torcoletti, Carlo Agostoni, Maja Di Rocco, Pranoot Tanpaiboon, Andrea Superti-Furga, Luisa Bonafé, Nur Arslan, Norberto Guelbert, Karoline Ehlert, Giedre Grigelioniene, Ratna Puri, Edward Schuchman, Pilar Gomez, Tatiana Gonzalez, Ricardo Yepez, Camilo Vargas, GRIP study group, Falcini Fernanda, Gemma Lepri, Alessandra Ferrari, Marco Matucci-Cerinic, Antonella Meini, Gian Marco Moneta, Emiliano Marasco, Rebecca Nicolai, Luisa Bracci-Laudiero, Olga Kopchak, Alexander Mushkin, Alexey Maletin, Catalina Mosquera, Rita A. Amorim, Juliana Molina, Gustavo Moreira, Flávia H. Santos, Melissa Fraga, Livia Keppeke, Vanessa M. Silva, Camila Hirotsu, Sergio Tufik, Maria Teresa Terreri, Vinícius L. Braga, Maria Beatriz Fonseca, Vania Schinzel, Maria Teresa R. Terreri, Liliana Jorge, Liana Guerra, Edson Amaro Junior, Maria Cristina Castiglione, Alessandra Tricarico, Emily Boulter, Andre Schultz, Kevin Murray, Fernanda Falcini, Stefano Stagi, Eleonora Bellucci, Ingrid H. R. Grein, Gecilmara Pileggi, Natália B. F. Pinto, Aline L. de Oliveira, Lyudmila Belyaeva, Rostislav Filonovich, Helena Khrustaleva, Larisa Zajtseva, Jaanika Ilisson, Chris Pruunsild, Olivier Gilliaux, Francis Corazza, Christophe Lelubre, on behalf of PANLAR Pediatric Rheumatology Study Group, Zoilo Morel, Claudia Saad-Magalhães C, Luis Lira, Mabel Ladino, Ruth Eraso, Ivonne Arroyo, Clovis Silva, Carlos Rose, and PANLAR Pediatric Rheumatology Study Group

Subjects
Pediatrics, RJ1-570, Diseases of the musculoskeletal system, RC925-935
Published
2017
Full Text
View/download PDF

141. Reliability and validity of hand-held dynamometer and hand-held sphygmomanometer for testing shoulder isometric external and internal rotator muscles strength

Author

Bettariga, Francesco, Lopomo, Nicola F., Civera, Fabio, Lazzarini, Stefano G., Mantovani, Lisa, Maestroni, Luca, Bettariga, Francesco, Lopomo, Nicola F., Civera, Fabio, Lazzarini, Stefano G., Mantovani, Lisa, and Maestroni, Luca

Abstract

Background: Shoulder strength evaluation is a recommended procedure in musculoskeletal rehabilitation. Aim: To examine hand-held sphygmomanometer (HHS) and hand-held dynamometer (HHD) intra- and inter-rater reliability during isometric shoulder external and internal rotation strength testing in prone rotation position in asymptomatic participants, and to compare these two testing modalities. Design: Reliability study. Methods: A total of 20 asymptomatic participants (27.7 ± 7.4 years; 77.1 ± 10.1 kg) attended a strength assessment consisting of HHS and HHD tests. Reliability was assessed using the intra-class correlation coefficient (ICC) with 95% confidence intervals (CI), coefficient of variation (CV) with 95%CI, and standard error of measurement (SEM). Pearson correlation and linear regression analysis were used to compare HHS and HHD testing modalities. Results: “Good” to “excellent” intra (ICC range = 0.896 to 0.979) and inter-rater reliability scores (ICC range = 0.850 to 0.978) were displayed during both HHS and HHD tests during internal and external rotation strength assessments. Linear relationships between HHS and HHD measures were found, with coefficients of determination (R 2) ranging between 0.60 and 0.79. Conclusion: HHS and HHD resulted to be reliable strength assessment modalities for clinical practice. These assessment modes can be equally valid in assessing intra and inter-limb asymmetries in isometric shoulder rotation strength. The affordability and availability of HHS in ordinary clinical settings can facilitate its implementation in musculoskeletal practice.

Published
2023

142. Yeast fermentation for the upcycling of PET monomers

Author

Senatore, V, Spreafico, I, Maestroni, L, Milanesi, R, Cannavacciuolo, C, Serra, I, Pescini, D, Branduardi, P, Senatore, VG, Senatore, V, Spreafico, I, Maestroni, L, Milanesi, R, Cannavacciuolo, C, Serra, I, Pescini, D, Branduardi, P, and Senatore, VG

Abstract

Plastic has become an indispensable material in many fields, with production increasing every year; however, most of the plastic waste is still incinerated or landfilled, and only 10% of the new plastic is recycled even once. Considering that plastic is derived from petroleum-based resources, this creates a worrying loss of resources and a cascade of environmental issues. Among all plastic, polyethylene terephthalate (PET) is the most produced polyester worldwide (56 Mt/year). This work focuses on the upcycling of PET monomers – terephthalic acid (TPA) and ethylene glycol (EG) – by yeast fermentation for the production of industrially relevant organic acids (protocatechuic acid, cis,cis-muconic acid, 3-carboxy-cis,cis-muconic acid, glycolic acid). Thanks to synthetic biology (EASY-MISE toolkit) and metabolic engineering, different Saccharomyces cerevisiae strains were created for the bioconversion of TPA and the use of EG as a carbon source. For the bioconversion of TPA, several genes from Ideonella sakaiensis were introduced; TPA toxicity on the new strains was assessed in microwell plates. Since EG assimilation has never been described in yeast, different medium combinations were tested for the assimilation of EG; in parallel, two synthetic metabolic pathways were introduced in S. cerevisiae for a more efficient assimilation. In silico constraint-based models are currently being developed to optimize growth and production on TPA and EG, and to shed light on the yeast native metabolism of the latter. Our research shows promising results in the biodegradation and upcycling of PET monomers by yeast fermentation, and it will become even more interesting thanks to the recent advances in enzymatic PET hydrolysis.

Published
2023

143. Random Variation

Author

Whitaker, Thomas B., Slate, Andrew B., Doko, M. Bruno, Maestroni, Britt M., Cannavan, Andrew, Whitaker, Thomas, editor, Slate, Andrew, editor, Doko, Bruno, editor, Maestroni, Britt, editor, and Cannavan, Andrew, editor

Published
2011
Full Text
View/download PDF

145. Designing Mycotoxin Sampling Plans

Author

Whitaker, Thomas B., Slate, Andrew B., Doko, M. Bruno, Maestroni, Britt M., Cannavan, Andrew, Whitaker, Thomas, editor, Slate, Andrew, editor, Doko, Bruno, editor, Maestroni, Britt, editor, and Cannavan, Andrew, editor

Published
2011
Full Text
View/download PDF

146. Sample Selection

Author

Whitaker, Thomas B., Slate, Andrew B., Doko, M. Bruno, Maestroni, Britt M., Cannavan, Andrew, Whitaker, Thomas, editor, Slate, Andrew, editor, Doko, Bruno, editor, Maestroni, Britt, editor, and Cannavan, Andrew, editor

Published
2011
Full Text
View/download PDF

147. Introduction

Author

Whitaker, Thomas B., Slate, Andrew B., Doko, M. Bruno, Maestroni, Britt M., Cannavan, Andrew, Whitaker, Thomas, editor, Slate, Andrew, editor, Doko, Bruno, editor, Maestroni, Britt, editor, and Cannavan, Andrew, editor

Published
2011
Full Text
View/download PDF

149. Pericardial diseases in pregnancy

Author

Lisa Serati, Vartan Mardigyan, Costanza Caccia Dominioni, Francesco Agozzino, Emanuele Bizzi, Lucia Trotta, Mariangela Nivuori, Silvia Maestroni, Enrica Negro, Massimo Imazio, and Antonio Brucato

Subjects
Cardiology and Cardiovascular Medicine
Published
2023

150. DNA, RNA e sintesi proteica muscolare

Author

Maestroni, Anna, Luzi, Livio, Codella, Roberto, Cooperation partner, Benedini, Stefano, Cooperation partner, Caumo, Andrea, Cooperation partner, Maestroni, Anna, Cooperation partner, Perseghin, Gianluca, Cooperation partner, Terruzzi, Ileana, Cooperation partner, and Zerbini, Gianpaolo, Cooperation partner

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results